 |
|
|
| |
Differential association of a chromosome 19 single nucleotide polymorphism (SNP: rs12979860) to outcome (early virologic response/sustained virologic response [EVR /SVR]) in naive vs. retreated HCV patients treated with IFN-based therapies
|
| |
| |
Reported by Jules Levin
AASLD 2010 Nov 2 Boston
T. Asselah,1 L. Essioux,2 P. Marcellin,1 M. W. Fried,3 D. M. Jensen,4 S. Germer,5 R. Benayed,5 T. Chu,6 A. Tietz,2 D. J. Chin,6 N. Shulman,6 J. Thommes,7 M. Laughlin,6 U. Lopatin6
1Hôpital Beaujon, Clichy, France; 2Roche, Basel, Switzerland; 3University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; 4Center for Liver Diseases, Chicago, IL, United States; 5Roche, Nutley, NJ, United States.; 6Roche, Palo Alto, CA, United States; 7Genentech, San Francisco, CA, United States
from Jules: a big question is the affect of IL28B when telaprevir or boceprevir is added to peg/rbv, the phase 3 studies presented at AASLD did not present these findings but I expect these data will be forthcoming. When however you add 2 or even more with 3 orals I expect the affect of IL28b will be diminished, in fact I think will essentially disappear, the more orals you have in the regimen the less likely IL28B will be to have any significance.
Association between rs12979860 and rs8099917
genotypes and cEVR in genotype 1 patients
-- Among treatment-naive patients, the cEVR rate was 49.6% overall,
65.5% in those with an rs12979860 C/C genotype and 19.2% in those with a T/T genotype (Figure 3a).
-- Although the cEVR rate was lower among previous non-responders (13.1%), the same trend is observed: the cEVR rate was 34.6% in those with the C/C genotype and 8.3% in those with the T/T genotype (Figure 3b).
-- In treatment-naive patients (Figure 3c) the cEVR rate was 59.4% in those with an rs8099917 T/T genotype and 28.6% in those with a G/G genotype.
-- In previous non-responders (Figure 3d) the cEVR rate was 20.9% in those with the rs8099917 T/T genotype and 5.6% in those with the G/G genotype.
|
| |
|
|
|
|
|
